Enveric Biosciences
Enveric Biosciences is a biotechnology company focused on improving patient outcomes by addressing adverse effects of cancer therapies and through novel mental health therapeutics. The company evaluates natural compounds, beginning with cannabinoids, to develop prescription medicines that meet unmet medical needs related to cancer treatment side effects. In parallel, Enveric develops neuroplastogenic small-molecule therapeutics for depression, anxiety, addiction, and other psychiatric disorders. Its program EB-003 seeks a first-in-class approach to enhance neuroplasticity without hallucinations, while EB-002 is a synthetic prodrug of psilocin under study for psychiatric conditions. The company aims to deliver targeted therapies that improve quality of life for patients through neurobiological mechanisms.
Top Regions
Top Stages
1 past transactions
MagicMed Industries
Acquisition in 2021
MagicMed Industries Inc. is a biotechnology company based in Calgary, Canada, focused on developing psychedelic-derived medicinal and consumer products. Established in 2020, the company is creating a library of novel derivative molecules, primarily targeting psilocybin, but also including other compounds like N,N-dimethyltryptamine (DMT). MagicMed's aim is to develop patented products that are more effective and safer for various psychological conditions. The company’s Psybrary serves as a molecular derivatives library, facilitating the innovation of psychedelic-derived pharmaceuticals, nutraceuticals, and consumer goods. This approach allows researchers to leverage unique processes and expertise that may not be available within traditional pharmaceutical and consumer goods companies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.